Kadimastem Ltd.
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
KDST | TA
Overview
Corporate Details
- ISIN(s):
- IL0011284614
- LEI:
- Country:
- Israel
- Address:
- Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona
- Website:
- https://www.kadimastem.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kadimastem Ltd. is a clinical-stage biotechnology company specializing in the development of regenerative medicine and cell therapies. The company leverages a proprietary technology platform for the industrial development and manufacturing of "off-the-shelf," allogeneic cell products derived from human embryonic stem cells. These therapies are designed for broad patient application to treat debilitating diseases, with a focus on conditions such as diabetes and neurodegenerative disorders. Kadimastem's approach aims to provide commercially viable, readily available treatments by creating universal cell-based products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-28 11:41 |
Investor Presentation
Company Presentation
|
English | 4.4 MB | ||
| 2024-05-28 11:41 |
Pre-Annual General Meeting Information
Company Presentation
|
Russian | 42.5 KB | ||
| 2024-02-12 13:47 |
Regulatory News Service
Excellence Investments Management and Securities will cease to operate as a mar…
|
Hebrew (modern) | 122.7 KB | ||
| 2022-12-13 16:05 |
Regulatory News Service
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
|
Hebrew (modern) | 177.9 KB | ||
| 2022-08-09 13:00 |
Regulatory News Service
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
|
English | 12.0 KB | ||
| 2022-06-08 13:00 |
Regulatory News Service
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards …
|
English | 12.1 KB | ||
| 2022-05-30 15:10 |
Regulatory News Service
Kadimastem Awarded Patent in Japan for AstroRx For ALS and Drug Screening
|
English | 10.6 KB | ||
| 2022-05-18 13:00 |
Regulatory News Service
Kadimastem Expands R&D Program to Include Multiple Sclerosis
|
English | 9.5 KB | ||
| 2022-03-03 14:05 |
Regulatory News Service
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) f…
|
English | 10.4 KB | ||
| 2021-12-13 13:00 |
Capital/Financing Update
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel I…
|
English | 10.6 KB | ||
| 2021-10-26 07:49 |
Share Issue/Capital Change
Kadimastem Raises $5 million In Private Placement
|
English | 10.5 KB | ||
| 2021-10-25 14:09 |
Share Issue/Capital Change
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
|
English | 10.5 KB | ||
| 2021-10-12 15:55 |
Legal Proceedings Report
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT)
Regar…
|
English | 9.5 KB | ||
| 2021-05-02 19:15 |
Investor Presentation
Company Presentation May 2021
|
English | 3.0 MB | ||
| 2021-05-02 19:15 |
Report Publication Announcement
Company Presentation May 2021
|
Russian | 42.5 KB |
Automate Your Workflow. Get a real-time feed of all Kadimastem Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kadimastem Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
